Partnership advances better neurovascular patient care by delivering timely insights to clinicians and improving clinical workflows
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Avicenna.AI, a leading provider of AI-based medical imaging solutions, announced that Viz.ai is integrating Avicenna.AI’s CINA-iPE and CINA-ASPECTS tools into the Viz.ai One™ platform. The combination of Avicenna’s two AI-based algorithms with Viz.ai’s care coordination capabilities provides radiologists and specialists with additional insights from computed tomography (CT) scans, to advance fast and accurate decision-making, driving better patient care.
“This expanded partnership with Avicenna.AI represents an important step forward in our mission to improve patient care through AI-powered, clinical workflows,” said Justin Ryea, director of product at Viz.ai. “By integrating CINA-iPE and CINA-ASPECTS into Viz.ai One, we are providing clinicians with an even more robust, all-in-one neurovascular solution that they can trust. This can help speed up the decision-making process and ensure that patients receive appropriate treatment as quickly as possible.”
Also Read: COTA and Guardant Health Partner to Advance Precision Oncology with AI and Real-World Data
The CINA-ASPECTS tool automatically assesses the ASPECTS (Alberta Stroke Program Early CT Score) from CT brain images, providing an objective and reliable measure of stroke severity. Avicenna received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CINA-iPE and CINA-ASPECTS tools in March 2024. The CINA-iPE tool detects incidental pulmonary embolism (PE), a life-threatening blockage in a lung artery, during routine CT scans and is intended to address delayed and missed findings. Unsuspected PE is a common finding in routine CT scans of the chest, but as little as 25% of emboli are reported during the initial interpretation. By combining Avicenna.AI’s technology with Viz.ai One, which facilitates real-time communication and coordination among care teams, clinicians can make faster, more informed decisions about treatment options for patients in need.
“We are thrilled to further our partnership with Viz.ai,” said Cyril Di Grandi, CEO of Avicenna.AI. “Incorporating CINA-iPE and CINA-ASPECTS into Viz.ai’s platform will allow us to bring a higher level of quality and efficiency to patient care. Our shared goal of empowering healthcare professionals with innovative tools to make critical decisions quickly and confidently can improve outcomes for more patients by helping to diagnose life-threatening conditions faster and facilitating appropriate follow-up care to patients when they need it.”
Source: Viz.ai
